Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable drugs.

Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of diabetes patients, and the company said it expects to seek regulatory approvals by the end of the year.

A new weight-loss pill taken daily could compete with injections like Ozempic, new research suggests. Patients, who all were obese and suffered from type 2 diabetes, took orforglipron for nine months as part of a trial, losing an an average of 16lbs.